| Discuss | Index | Tracked By |
Biodel Inc. Posts Q4 Loss of $0.47, Wider Y/Y
BIOD Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 04, 04:31PM from (www.streetinsider.com) more ...
Biodel Reports First Quarter Fiscal Year 2010 Financial Results
BIOD Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 04, 04:00PM from (www.businesswire.com) Biodel Inc. (Nasdaq: BIOD) today reported financial results for the first fiscal quarter ended December 31, 2009. First Quarter more ...
Swine Flu Antiviral Helps BioCryst Crush Estimates in Q4
BCRX APT RHHBY NVAX INO GNBT SVA NVS SNY Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 04, 10:35AM from (www.tickerspy.com) While select swine flu players have seen their pops and drops, BioCryst Pharmaceuticals (BCRX) may have emerged as the small-cap champion of the 2009 pandemic. more ...
More Heavyweights Weigh In With Solid Earnings
PFE CSCO HDIX RL NETL CMCSA V Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 03, 04:43PM from (www.tickerspy.com) Stocks had a mixed day, breaking the market's two-day winning streak. A few heavyweights reported earnings after the bell more ...
Home Diagnostics Buyout Powers Diabetes Segment
NVO AMLN HDIX MNKD GNBT ARRY Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 03, 12:03PM from (www.tickerspy.com) Home Diagnositics (HDIX) is soaring today after the company announced a definitive merger agreement with Nipro Corporation. more ...
Top Day Trader Alerts
HDIX MYGN VRSN ALVR APKT NETL ANX AUXL CTRP DDSS NWS WU SOLR Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - February 03, 08:56AM from (247wallst.com) These are this morning's top day trader and active trader alerts with a brief explanation of the news behind the moves: more ...
Major Premium Buyout at Home Diagnostics, A Return To Old Prices
HDIX Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - February 03, 08:35AM from (247wallst.com) Home Diagnostics, Inc. (NASDAQ: HDIX) is this morning's top pre-market gainer, on news of a buyout. The company has agreed more ...
Home Diagnostics, Inc. Agrees to Be Acquired by Nipro Corporation; Companies Sign Definitive Agreement
HDIX Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 03, 06:00AM from (www.businesswire.com) Home Diagnostics, Inc. (NASDAQ: HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today more ...
Array BioPharma Tops Q2 Views
ARRY Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 01, 04:33PM from (www.streetinsider.com) more ...
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2010
ARRY Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 01, 04:33PM from (www.businesswire.com) Array BioPharma Inc. (Nasdaq: ARRY) today reported financial results for the second quarter of fiscal 2010. Array reported more ...
MannKind Posts Wider than Estimated Q4 Loss of $0.53
MNKD Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 01, 04:01PM from (www.streetinsider.com) more ...
Insulet Corporation to Report Fourth Quarter and Full Year 2009 Financial Results on Tuesday, February 9, 2010
PODD Linked by marketwire ( track newsfeed | ignore newsfeed ) - February 01, 09:40AM from (www2.marketwire.com) Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management more ...
Biodel to Report First Quarter Fiscal Year 2010 Financial Results on February 4, 2010
BIOD Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - February 01, 07:00AM from (www.businesswire.com) Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2010 financial results on February 4, 2010. Following more ...
Amylin Misses Street's Q4 Views
AMLN Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - January 27, 04:06PM from (www.streetinsider.com) more ...
Amylin Pharmaceuticals Reports 2009 Financial Results
AMLN Posted by PR Newswire ( track newsfeed | ignore newsfeed ) - January 27, 04:05PM SAN DIEGO, Jan. 27, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results more ...
Array BioPharma Names Bengt Bergstrom, M.D., Ph.D., Vice President, Clinical Development
ARRY Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - January 26, 04:01PM from (www.businesswire.com) Array BioPharma Inc. (NASDAQ: ARRY) today announced that Bengt Bergstrom, M.D., has joined the Company as Vice President more ...
Analyst Upgrades, Downgrades and Initiations: AMLN, CI, CTXS, HSY, KRA, TSCO, TXN ...
HSY TXN TNB NVO CI PLXS CTXS AMLN PXP TSCO LXK SLXP NILE VMW GXDX WBD KRA AWK CIE LSTZA Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - January 26, 11:40AM from (www.bloggingstocks.com) Analyst Upgrades Jefferies upgraded Citrix Systems (CTXS) to buy from hold and raised its target to $48 more ...
Top Day Trader Alerts
LLY AAPL NVO MRNA CTXS AMLN VMW Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - January 26, 09:06AM from (247wallst.com) These are the top day trader and active trader alert stocks. We have more details and analysis via a link to each story over at VSInvestor.com: more ...
Amlylin Pharma : Upgraded to Buy at Citigroup; Street high target of $27
AMLN Linked by Notable Calls ( track newsfeed | ignore newsfeed ) - January 26, 06:23AM from (notablecalls.blogspot.com) Amylin Pharma (NASDAQ:AMLN) is getting lots of very positive commentary this morning after the FDA issued a press release more ...
MannKind Corporation to Hold 2009 Fourth Quarter and Full Year Financial Results Conference Call on February 1, 2010
MNKD Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - January 25, 05:34PM from (www.businesswire.com) MannKind Corporation (Nasdaq: MNKD) will release its 2009 fourth quarter and full year financial results on Monday, February more ...
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2010 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.
|
|